BioCentury
ARTICLE | Politics, Policy & Law

Biopharma execs push back on Rep. Porter’s push to rein in M&A

Congressional report says biopharma acquisitions kill innovation, calls for FTC reviews, restraints. 

February 2, 2021 1:17 AM UTC

Rep. Katie Porter (D-Calif.), a rising voice in the progressive wing of the Democratic Party, has released a report that portrays biopharma mergers and acquisitions as harmful to innovation and recommends laws that would slow or restrict M&A.

The report fundamentally misrepresents the biopharma ecosystem, according to biopharma executives who spoke to BioCentury, who say the policies it advocates would stunt the biotech industry...